We explore the groundbreaking trial of Amivantamab combined with chemotherapy in treating non-small-cell lung cancer - specifically those presenting the EGFR exon 20 insertions. We delve into the trial's promising results, the significant increase in progression-free survival, and the potential of this new approach to revolutionize lung cancer treatment.
Original Article
www.nejm.org/d...
🎙️ State of Health Podcast: open.spotify.c...
Join this channel to get access to perks:
/ @medzcool
DISCLAIMER
⚠️ For Healthcare Practitioners: This content is provided only for medical education. Although the authors have made every effort to provide the most up-to-date, evidence-based medical information, this content should not necessarily be considered the standard of care. It may not reflect individual practices in other geographic locations. It should be considered in the context of other medical educational resources.
⚠️ For the Public: This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. You should contact your own physician or other qualified healthcare providers with any questions you may have regarding your medical condition. Do not disregard professional medical advice or delay seeking it based on information from this content. Relying on information provided in this content is done at your own risk. In a medical emergency, contact your physician or call 9-1-1 immediately.